Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata: a Pilot Study of Patient Tolerability

This is an interventional pilot study assessing the tolerability of needle-free delivery administration of ILTA with the Med-Jet as an alternative to conventional syringe and needle in patients with patchy pediatric alopecia areata. There will be a total of four (4) or five (5) visits necessary for study participation. The investigators hypothesize that the Med-Jet will have acceptable pain tolerability, efficacy, safety, and a positive impact on patient quality of life.

Inclusion Criteria:

• Diagnosed with alopecia areata by either:

  • A board-certified dermatologist, OR
  • Dermatology Nurse Practitioner, OR
  • Skin punch biopsy

• Patient has at least 2 alopecic patches each measuring at least 2 cm2 and are…

  • Located on contralateral body sites OR
  • Within the same body site but separated by ≥ 1 cm

• Patient is a candidate for intralesional triamcinolone.

• Patient able to give informed assent under IRB approval procedures when appropriate.

• At least one parent or guardian is able to provide informed consent.

Exclusion Criteria:

• Patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasis pattern.
• Known allergy or hypersensitivity to triamcinolone acetonide
• Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.
• Patient is unable/unwilling to provide informed assent when applicable.
• Known medical diagnosis or use of a medication that alters pain response at time of injection.
• Active infection at site designated for injection.
• If currently being treated for alopecia areata, the current treatment regimen has been started within less than 4 weeks of screening.